Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Free Report) have received a consensus recommendation of “Hold” from the seven brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $6.2333.
Several equities research analysts have recently commented on IRWD shares. Zacks Research downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Wall Street Zen raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Sunday, May 17th. Citizens Jmp boosted their target price on shares of Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the stock a “market outperform” rating in a research report on Thursday, February 26th. Jefferies Financial Group reissued a “hold” rating and set a $3.70 target price on shares of Ironwood Pharmaceuticals in a research report on Thursday, February 26th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, April 27th.
View Our Latest Research Report on IRWD
Ironwood Pharmaceuticals Price Performance
Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) last posted its earnings results on Thursday, May 7th. The biotechnology company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). The business had revenue of $106.51 million for the quarter, compared to the consensus estimate of $92.11 million. Ironwood Pharmaceuticals had a negative return on equity of 39.65% and a net margin of 28.26%. On average, equities research analysts expect that Ironwood Pharmaceuticals will post 0.88 earnings per share for the current fiscal year.
Insider Transactions at Ironwood Pharmaceuticals
In other Ironwood Pharmaceuticals news, Director Alexander J. Denner sold 6,730,800 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $3.05, for a total value of $20,528,940.00. Following the completion of the sale, the director directly owned 9,188,635 shares of the company’s stock, valued at approximately $28,025,336.75. This represents a 42.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 9.30% of the company’s stock.
Institutional Investors Weigh In On Ironwood Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in the company. Krilogy Financial LLC lifted its stake in shares of Ironwood Pharmaceuticals by 9.8% during the 1st quarter. Krilogy Financial LLC now owns 33,194 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 2,971 shares in the last quarter. ProShare Advisors LLC lifted its stake in shares of Ironwood Pharmaceuticals by 9.6% during the 4th quarter. ProShare Advisors LLC now owns 36,315 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 3,170 shares in the last quarter. Integrated Wealth Concepts LLC lifted its stake in shares of Ironwood Pharmaceuticals by 21.4% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 3,406 shares in the last quarter. DGS Capital Management LLC lifted its stake in shares of Ironwood Pharmaceuticals by 42.8% during the 1st quarter. DGS Capital Management LLC now owns 14,883 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 4,458 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV lifted its stake in shares of Ironwood Pharmaceuticals by 7.8% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 76,951 shares of the biotechnology company’s stock valued at $259,000 after buying an additional 5,598 shares in the last quarter.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.
Featured Stories
- Five stocks we like better than Ironwood Pharmaceuticals
- Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
- MarketBeat Week in Review – 05/18 – 05/22
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
